Literature DB >> 3511463

Classical bacterial diarrhea: perspectives and update--Salmonella, Shigella, Escherichia coli, Aeromonas and Plesiomonas.

M B Rennels, M M Levine.   

Abstract

Impressive advancements in our understanding of the mechanisms of diarrhea production and of the epidemiologic importance of these "classical" bacterial enteropathogens have been accomplished, but many areas are in need of further exploration. The recent development of gene probes and enzyme-linked immunosorbent assays for the identification of EPEC, ETEC and EIEC will enhance immeasurably the ability to carry out large scale epidemiologic studies which are still needed to clarify the global importance of these pathogens in infantile diarrhea. For some of these organisms pathogenic mechanisms remain incompletely understood and the role of antibiotics is not well-established. The delineation of virulence factors, immunity and the construction of attenuated strains through DNA recombination technology are bringing the worthy goal of prevention through vaccination into view. These advances should not, however, detract attention from the primary reason that these bacteria continue to be a major cause of childhood morbidity and mortality in the developing world, which is lack of adequate sanitation. Efforts to provide clean water, safe waste disposal and hygiene education need to proceed in conjunction with development of vaccines.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3511463

Source DB:  PubMed          Journal:  Pediatr Infect Dis        ISSN: 0277-9730


  2 in total

1.  Escherichia coli gastroenteritis: making sense of the new acronyms. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1987-02-01       Impact factor: 8.262

2.  Quantitative analysis and partial characterization of cytotoxin production by Salmonella strains.

Authors:  S Ashkenazi; T G Cleary; B E Murray; A Wanger; L K Pickering
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.